OmicsGlioma - personalisierte Therapie für Hirntumore

The OmicsGlioma Consortium

 

Publikationen und Präsentationen

 

Publikationen in Fachzeitschriften

 

 

Buzdin A, Sorokin M, Garazha A, Glusker A, Aleshin A, Poddubskaya E, Sekacheva M, Kim E, Gaifullin N, Giese A, Seryakov A, Rumiantsev P, Moshkovskii S, Moiseev A.  RNA sequencing for research and diagnostics in clinical oncology.  Semin Cancer Biol. 2020 Feb;60:311-323. Review.

 

Kim EL, Sorokin M, Kantelhardt SR, Kalasauskas D, Sprang B, Fauss J, Ringel F, Garazha A, Albert E, Gaifullin N, Hartmann C, Naumann N, Bikar SE, Giese A, Buzdin A.  Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma. Cancers (Basel). 2020 Feb 24;12(2):520. 

 

Zolotovskaia MA, Sorokin MI, Petrov IV, Poddubskaya EV, Moiseev AA, Sekacheva MI, Borisov NM, Tkachev VS, Garazha AV, Kaprin AD, Shegay PV, Giese A, Kim E, Roumiantsev SA, Buzdin AA.  Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. Int J Mol Sci. 2020 Feb 26;21(5):1580. 

 

Kalasauskas D, Sorokin M, Sprang B, Elmasri A, Viehweg S, Salinas G, Opitz L, Rave-Fraenk M, Schulz-Schaeffer W, Kantelhardt SR, Giese A, Buzdin A, Kim EL.  Diversity of Clinically Relevant Outcomes Resulting from Hypofractionated Radiation in Human Glioma Stem Cells Mirrors Distinct Patterns of Transcriptomic Changes. Cancers (Basel). 2020 Mar 1;12(3):570. 

 

 

Buzdin A, Sorokin M, Garazha A, Sekacheva M, Kim E, Zhukov N, Wang Y, Li X, Kar S, Hartmann C, Samii A, Giese A, Borisov N.  Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs. Semin Cancer Biol. 2018 Dec;53:110-124. Review.

 

 

Enam A, Kalasauskas D, Buzdin A, Kim E, Giese A.  Molecularly-based diagnostics and individualized therapy of malignant brain tumors from a global perspective. under revision 2016

 

Barrantes-Freer A, Renovanz M, Pardo LA, Giese A, Kim EL. CD133 expression is not synonymous to immunoreactivity for AC133 and reflects the stage of cell cycle in glioma cells. PlosOne 18:10(6) e0130519, 2015

 

Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY, Borisov NM.

Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front Genet. 2014 25;5:55

Lezhnina K, Kovalchuk O, Zhavoronkov AA, Korzinkin MB, Zabolotneva AA, Shegay PV, Sokov DG, Gaifullin NM, Rusakov IG, Aliper AM, Roumiantsev SA, Alekseev BY, Borisov NM, Buzdin AA. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget. 2014 5(19):9022-32.

 

Renovanz, M. and E.L. Kim, Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Molecular mechanisms of cellular stress responses in cancer and their therapeutic implications, Front Oncol 2014: p. 121

Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE, Buzdin AA, Borisov NM, Aliper AM, Garazha AV, Rubtsov PM, Stocking C, Prassolov VS. Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia. 2014 28(11):2222-8.

 

Barrantes-Freer A, Kim E, Bielanska J, Giese A, Mortensen LS, Schulz-Schaeffer WJ, Stadelmann C, Brück W, Pardo LA. Human glioma-initiating cells show a distinct immature phenotype resembling but not identical to NG2 glia. J Neuropathol Exp Neurol, 72:307-24, PMID: 23481707, 2013

 

Neurochirurgie Universitätsmedizin Mainz
oncobox_icon.png

© 2020 OmicsGlioma Konsortium

  • Facebook Social Icon